Product Detail

Ephedrine Sulfate in 0.9% Sodium Chloride Injection 50 mg/10 mL

Unit of Sale NDC 14789-0250-10

Size
10 mL vials
Unit of Sale
10 vials per carton
Type
Rx
Storage
Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]
Active
50 mg ephedrine sulfate
Inactives
Sodium chloride
Preservative-free
Yes
Latex-free
Yes
Allergen-free
Yes

Order directly through your wholesaler or from Customer Service at (888) 806-4606

Unit of sale NDC 14789-0250-10

Size: 10 mL vials

Unit of sale: 10 vials per carton

Under the Controlled Substances Act (CSA), your state may require additional licensing for dispensing EMERPHED ready-to-use ephedrine.

For questions, please contact customer service at 888‑806‑4606.

Wholesaler
Item Number
Cardinal
5644521
McKesson
1538644
Morris & Dickson
903617
Amerisource Bergen
10235817

The Nexus Difference

Committed to Quality — From Molecules to Medicine

Starting with the source

  • After years of research & development, EMERPHED completed a rigorous FDA approval process
  • Consumers and health professionals rely on the drug approval process for verification of safety, effectiveness, and quality1

Partnering with the right CMO*

  • Based in North America and Europe—highly regulated markets with strong compliance histories

*Contract Manufacturing Organization

Applying extra quality assurance

  • EMERPHED is terminally sterilized which means the product is sterilized in its final container, ensuring a high level of sterility assurance, aligning with FDA guidelines and cGMP2
  • Testing does not occur just once—every single batch goes through rigorous testing before making it to the pharmacy shelf

Delivering when others fall short

  • No supply disruption vs. 203 generic injectable shortages with other suppliers3
What important safety information should I know?

CONTRAINDICATIONS

None

WARNINGS AND PRECAUTIONS

EMERPHED can cause pressor effects with concomitant use with oxytocic drugs. Can also cause tachyphylaxis with repeated administration of ephedrine.

ADVERSE REACTIONS

Most common adverse reactions during treatment: nausea, vomiting, and tachycardia.

To report SUSPECTED ADVERSE REACTIONS, contact Nexus Pharmaceuticals at (855) 642-2594 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

  • Interactions that Augment Pressor Effect: clonidine, oxytocin and oxytocic drugs, propofol, monoamine oxidase inhibitors (MAOIs), and atropine. Monitor blood pressure.

  • Interactions that Antagonize the Pressor Effect: Antagonistic effects with α-adrenergic antagonists, β-adrenergic antagonists, reserpine, quinidine, mephentermine. Monitor blood pressure.

  • Guanethidine: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. Monitor blood pressure and adjust the dosage of pressor accordingly.

  • Rocuronium: Ephedrine may reduce the onset time of neuromuscular blockade when used for intubation with rocuronium if administered simultaneously with anesthetic induction. Be aware of this potential interaction. No treatment or other interventions are needed.

  • Epidural anesthesia: Ephedrine may decrease the efficacy of epidural blockade by hastening the regression of sensory analgesia. Monitor and treat the patient according to clinical practice.

  • Theophylline: Concomitant use of ephedrine may increase the frequency of nausea, nervousness, and insomnia. Monitor patient for worsening symptoms and manage symptoms according to clinical practice.

  • Cardiac glycosides: Giving ephedrine with a cardiac glycoside, such as digitalis, may increase the possibility of arrhythmias. Carefully monitor patients on cardiac glycosides who are also administered ephedrine.

OVERDOSAGE

Overdose of EMERPHED can cause a rapid rise in blood pressure. In the case of an overdose, careful monitoring of blood pressure is recommended. If blood pressure continues to rise to an unacceptable level, parenteral antihypertensive agents can be administered at the discretion of the clinician.

INDICATIONS AND USAGE

Ephedrine Sulfate injection is an alpha- and beta- adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.